Adjuvant aromatase inhibitors and emerging quality-of-life considerations

Susanne Briest, Vered Stearns

Research output: Contribution to journalEditorial

Abstract

In summary, while AIs are a welcome addition to the repertoire of endocrine interventions for the treatment of breast cancer, further studies are warranted to elucidate their long-term effects. Other tumor-related characteristics and host factors may predict not only efficacy but also AI-associated safety. Early recognition and management of adverse effects is crucial for maintaining adherence and achieving the maximum benefit from therapy. Additional follow-up is required to establish the long-term safety of the agents. Until further information becomes available, clinicians are encouraged to utilize AIs in the setting in which they have been studied and approved.

Original languageEnglish (US)
Pages (from-to)1-4
Number of pages4
JournalExpert Review of Anticancer Therapy
Volume8
Issue number1
DOIs
StatePublished - Jan 1 2008

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Adjuvant aromatase inhibitors and emerging quality-of-life considerations'. Together they form a unique fingerprint.

  • Cite this